Holen Sie sich die Stockscreener-App
7.16
12.58%
0.80
Vorhandelsmarkt:
7.39
0.23
+3.21%
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Positive Phase II data on Verrica and Lytix’ ruxotemitide in BCC - The Pharma Letter
Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - Finansavisen
In 9 patients, Verrica's skin cancer drug shrank untreated tumors 67% - Stock Titan
Verrica Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
MSN Money - MSN
Verrica schedules May 12 webcast for Q1 results and update - Stock Titan
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ... - Caledonian Record
Verrica Pharmaceuticals to Report First Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Common Warts Pipeline 2026: Therapies Under Investigation, - openPR.com
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
[ARS] Verrica Pharmaceuticals Inc. SEC Filing - Stock Titan
[DEF 14A] Verrica Pharmaceuticals Inc. Definitive Proxy Statement - Stock Titan
Verrica Pharmaceuticals (VRCA) Stock Sector Rotation (Momentum Building) 2026-04-18Pre Earnings - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ) - The Globe and Mail
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
VRCA: Strong commercial growth and advancing late-stage pipeline position the company for major catalysts - TradingView
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting - MyChesCo
Block Trades: Is Verrica Pharmaceuticals Inc benefiting from innovation trendsM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Rallies: Is Verrica Pharmaceuticals Inc stock good for income investors2026 Decliners & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Big Picture: Will Verrica Pharmaceuticals Inc announce a stock split2026 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
What is the future of Verrica Pharmaceuticals (VRCA) Stock | Price at $5.40, Down 7.38%High Interest Stocks - Xã Thanh Hà
EPS Watch: Is Verrica Pharmaceuticals Inc stock a value trapWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Verrica Pharmaceuticals announces acceptance of late-breaking abstract highlighting potential abscopal effect of VP-315 for the treatment of basal cell carcinoma at the upcoming 2026 Society for Investigative Dermatology annual meeting - marketscreener.com
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting - GlobeNewswire
Chart Watch: Will Verrica Pharmaceuticals Inc announce a stock splitMarket Volume Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks Research - MarketBeat
Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Will Verrica Pharmaceuticals (VRCA) Stock Miss Expectations | Price at $5.98, Up 9.32%Stock Picks - Xã Vĩnh Công
VRCA Stock Analysis: Verrica Pharmaceuticals Inc. $5.47 Price Trend Deep Dive - Cổng thông tin điện tử tỉnh Lào Cai
Published on: 2026-04-01 04:27:23 - baoquankhu1.vn
Market Trends: How does Verrica Pharmaceuticals Inc score in quality rankingsProfit Target & Safe Swing Trade Setups - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest - MarketBeat
Published on: 2026-03-31 18:08:06 - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart.com
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - weeklyvoice.com
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - weeklyvoice.com
Verrica Encounters Legal Trigger—Could This Be an Undervalued Opportunity for a Short Squeeze? - Bitget
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
FinancialContentVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - FinancialContent
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):